NASDAQ · SLGL
Sol-Gel Technologies Ltd.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SLGL: Nov 19, 2026
Sol-Gel Technologies Ltd. Ordinary Shares is estimated to report earnings on 11/19/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.54. The reported EPS for the same quarter last year was $-2.13.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.54 | $-1.54 | $-1.54 | 1 |
| Dec 2026 | $-1.77 | $-1.77 | $-1.77 | 1 |
| Mar 2027 | $-1.14 | $-1.14 | $-1.14 | 1 |
| Jun 2027 | $-1.08 | $-1.08 | $-1.08 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat · Fintel · RTTNews- Zacks · Oct 29, 6:05 PM EDTSupernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue EstimatesSupernus (SUPN) delivered earnings and revenue surprises of +89.80% and +1.39%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 16, 3:04 AM EDTNew Strong Buy Stocks for October 16thUGP, SCSC, MRKR, SLGL and MEOH have been added to the Zacks Rank #1 (Strong Buy) List on October 16, 2026.
- MarketBeat · Oct 14, 11:02 PM EDTSol-Gel Eyes 2028 Launch as SGT-610 Nears Pivotal Gorlin Syndrome DataSol-Gel Technologies (NASDAQ:SLGL) outlined its development and commercialization plans for SGT-610, a topical patidegib treatment being studied to reduce new basal cell carcinomas (BCCs) in patients with Gorlin syndrome, a rare inherited disorder associated with recurrent skin c
- Fintel · Oct 14, 2:19 PM EDTCantor Fitzgerald Initiates Coverage of Sol-Gel Technologies at OverweightCantor Fitzgerald initiated coverage of Sol-Gel Technologies (NASDAQCM:SLGL) (DB:4SG) with a Overweight recommendation on October 14, 2026. Sol-Gel Technologies Ltd. is a pharmaceutical company based in Israel specializing in dermatology, focused on developing proprietary branded
- Zacks · Oct 8, 11:00 AM EDTSolGel Technologies (SLGL) Upgraded to Buy: Here's WhySolGel Technologies (SLGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks · Sep 17, 9:55 AM EDTSolGel Technologies (SLGL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?SolGel Technologies (SLGL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for
- RTTNews · Aug 20, 11:19 AM EDTSol-Gel Posts Net Loss In Q2; Phase 3 Gorlin Results Due In November 2026(RTTNews) – Sol-Gel Technologies, Ltd. (SLGL), an Israeli dermatology company, on Thursday released financial results, reporting a net loss for the second quarter compared to a profit a year ago, due to lower revenue.
- Zacks · Aug 13, 9:25 AM EDTMeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass EstimatesMeiraGTx (MGTX) delivered earnings and revenue surprises of +538.46% and +20,637.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 10, 5:55 PM EDTMetagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue EstimatesMetagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -15.87% and -120.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 3, 7:50 AM EDTSupernus Pharmaceuticals (SUPN) Matches Q2 Earnings EstimatesSupernus (SUPN) delivered earnings and revenue surprises of 0.00% and +6.84%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 29, 8:35 PM EDTBausch Health (BHC) Q2 Earnings and Revenues Beat EstimatesBausch (BHC) delivered earnings and revenue surprises of +31.25% and +7.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 21, 11:20 PM EDTTop Biotech Gainers: WGRX Rebrands, PVLA Nears FDA Milestone, ASBP On Track For NDA Filing(RTTNews) – Today's top biotech gainers include Wellgistics following its rebranding, Femasys, which recently resolved its Nasdaq compliance issue, Vor Bio with continued progress in its Telitacicept program, and Sol-Gel Technologies as investors look ahead to key SGT-610 Phase 3
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Sol-Gel Technologies Ltd. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.